| 证券代码：300630 | 证券简称：普利退 公告编号：2025-056 | | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | 海南普利制药股份有限公司 关于公司股票及可转换公司债券进入退市整理期交易的 第五次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"），于退市整理期届满的次一交易日摘牌，公司股票及 可转债终止上市。 7. 公司股票已被调出深股通标的，深股通投资者只能卖出股票。后续公司 股票进入退市板块后，深股通投资者可能无法进行股票转让，提请深股通投资 者注意投资风险。 8. 根据《退市公司可转换公司债券管理规定》第三十条，退市可转债自交 易所摘牌后至挂牌期间不得实施转股、赎回、回售等操作，挂牌后需重新提交 转股、赎回、回售等相关信息。 投资者已提交转股、赎回、回售等操作申请，摘牌前未实施完成的，需待 可转债在股转公司挂牌后重新提交操作申请，敬请投资者注意。 9. 终止上市后，公司的信息披露指定媒体 ...

Core Viewpoint - Hainan Puli Pharmaceutical Co., Ltd. has announced that its stock and convertible bonds will enter a delisting arrangement period, with the last trading day set for May 21, 2025, following a decision by the Shenzhen Stock Exchange to terminate their listing [1][2][4]. Group 1: Delisting Announcement - The company received a notice from the Shenzhen Stock Exchange on April 18, 2025, regarding the termination of its stock and convertible bonds listing [2]. - The delisting arrangement period began on April 28, 2025, lasting for fifteen trading days, with the final trading day expected to be May 21, 2025 [4][5]. - During the delisting period, the stock will be traded on the risk warning board of the Shenzhen Stock Exchange, with no price fluctuation limits on the first trading day, followed by a 20% limit on subsequent days [3][4]. Group 2: Trading Rules and Restrictions - The stock and convertible bonds will not be subject to price fluctuation limits on the first trading day of the delisting period, but will have a 20% limit thereafter [3][4]. - Investors are advised that after the delisting, they will not be able to execute conversion, redemption, or repurchase operations until the bonds are listed again [2][5]. - The company will not plan or implement any major asset restructuring during the delisting period [5]. Group 3: Investor Communication - The company will issue risk warning announcements regarding the delisting every five trading days during the first ten trading days and daily during the last five trading days of the delisting period [4]. - Investors are encouraged to refer to the official announcements published on the designated information disclosure media for accurate information [6].

| 证券代码：300630 | 证券简称：普利退 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | | 海南普利制药股份有限公司 关于公司股票及可转换公司债券进入退市整理期交易的 第四次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）股票及可转换公司债 券（以下简称"可转债"），于退市整理期届满的次一交易日摘牌，公司股票及 可转债终止上市。 2. 公司股票及可转债进入退市整理期的起始日为 2025 年 4 月 28 日，预计 最后交易日期为 2025 年 5 月 21 日。 3. 公司股票及可转债将在退市整理期交易十五个交易日，截至 2025 年 5 月 14 日公司股票及可转债已交易 10 个交易日，剩余 5 个交易日，交易期满将 被终止上市，敬请投资者审慎投资、注意风险。 4. 公司股票及可转债在退市整理期交易期间，公司将不筹划或实施重大资 产重组。可转债在退市整理期的相关交易规则、投资者适当性安排请 ...

New Stock Offerings - ST Xinchao (600777) is in the offer period from April 23, 2025, to May 22, 2025[1] - Polytron Technologies (300630) has 5 trading days remaining until the last trading day[1] - ST Cube (300344) has an announcement dated May 14, 2025, but no specific details provided[1] Trading Alerts - ST Zhongcheng (300208) reported severe abnormal fluctuations on April 29, 2025[1] - ST Hu Ke (600608) and ST Hua Rong (600421) both have announcements dated May 14, 2025, with no further details[1] - ST Zhengping (603843) has an announcement dated May 13, 2025, with no specific details provided[1] Market Trends - Multiple stocks, including ST Yanzhen (603389) and ST Chuangxing (600193), have announcements dated May 14, 2025, indicating potential market volatility[1] - The report highlights a significant number of stocks under observation for abnormal trading activities, suggesting increased market scrutiny[2]

Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [6]. Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11]. - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13]. - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16]. Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 sectors [2][11]. - The year-to-date performance shows a 1.19% increase, ranking 15th among the sectors [13]. 2. Key Company Announcements - Key companies such as Kelly Tai, BGI Genomics, and Dongfang Bio reported varying financial results, with some showing significant declines in net profit [21]. 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22]. - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22]. - The report suggests that the innovative drug sector is entering a phase of realization, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22]. 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%), Haichuang Pharmaceutical (+25.85%), and Jinhao Medical (+25.32%) [3][20]. - Conversely, the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20].

Group 1 - Longjiang Transportation plans to reduce its shareholding by no more than 3% of the company's total shares, amounting to 39.4764 million shares, from June 4, 2025, to September 3, 2025 [1] - Shuangyi Technology intends to acquire 100% equity of Marky Industries Pty Ltd and specific assets for approximately AUD 18 million [1] - Haikong Air Conditioning's controlling shareholder has received a bank loan commitment of up to CNY 32 million for share repurchase [2] Group 2 - Zhaowei Electromechanical's shareholder plans to reduce its stake by no more than 1.50%, equating to 3.6031 million shares, from June 5, 2025, to September 4, 2025 [2] - Zhongwen Online's directors and senior management plan to collectively reduce their holdings by no more than 877,100 shares, representing 0.1203% of the total shares [2] - Liding Optoelectronics' shareholders plan to reduce their holdings by no more than 3%, totaling 12.2113 million shares, from June 5, 2025, to September 4, 2025 [4] Group 3 - Luvi Optoelectronics' shareholder plans to reduce its stake by no more than 1%, amounting to 1.9333 million shares, from June 4, 2025, to September 4, 2025 [5] - Jiejia Weichuang's controlling shareholder and concerted parties plan to reduce their holdings by no more than 0.72%, totaling 250,000 shares [7] - Yancoal Energy will no longer acquire control of Highfield Resources due to a new investment from Qinghai Salt Lake Industry Co., Ltd. [9] Group 4 - Yongdong Co., Ltd. plans to reduce its shareholding by no more than 1.26%, equating to 473,380 shares, from June 5, 2025, to September 4, 2025 [11] - Sanqi Interactive Entertainment plans to distribute a cash dividend of CNY 2.10 per 10 shares [12] - Salt Lake Co., Ltd. intends to acquire Highfield Resources for approximately USD 300 million to become its largest shareholder [13] Group 5 - Hainan Haiyao's shareholder plans to reduce its stake by no more than 3%, totaling 38.921 million shares, within 90 days after the announcement [14] - Lifang Pharmaceutical plans to transfer 2.2184% equity of Nanjing Mainowei Pharmaceutical Technology Co., Ltd. for CNY 22.1837 million [16] - Zhiyou Technology's shareholders plan to reduce their holdings by no more than 2.99%, totaling 11.9986 million shares, from June 4, 2025, to September 3, 2025 [18] Group 6 - Puli Tui has applied for a review of the Shenzhen Stock Exchange's decision to terminate its listing [19] - Saimo Intelligent's shareholder plans to reduce its stake by no more than 3%, equating to 16.0659 million shares, from June 4, 2025, to September 3, 2025 [20] - Entropy Technology is planning to acquire 55% equity of Longzhiyuan to gain control [21] Group 7 - Nanjing Chemical Fiber plans to acquire 100% of Nanjing Process Equipment Manufacturing Co., Ltd. through asset swaps and cash payments [22] - Beijing Lier intends to invest CNY 200 million in Shanghai Zhenliang Intelligent Technology Co., Ltd. [23]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码：300630 | 证券简称：普利退 | 公告编号：2025-054 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转退 | | 海南普利制药股份有限公司 关于公司向深圳证券交易所申请复核的公告 特别提示： 1. 海南普利制药股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日收 到深圳证券交易所（以下简称"深交所"）《关于海南普利制药股份有限公司股 票及可转换公司债券终止上市的决定》（深证上〔2025〕357 号）。深圳证券交易 所决定终止公司股票及可转换公司债券（以下简称"可转债"）上市。 2. 公司股票及可转债进入退市整理期的起始日为 2025 年 4 月 28 日，退市 整理期为十五个交易日，预计最后交易日期为 2025 年 5 月 21 日。公司股票及 可转债于退市整理期届满的次一交易日摘牌并终止上市。 3. 公司股票及可转债在退市整理期交易期间，公司将不筹划或实施重大资 产重组。可转债在退市整理期的相关交易规则、投资者适当性安排请投 ...

Group 1 - Since May, several companies including *ST Zhongcheng, *ST Renle, *ST Hengli, and *ST Gongzhi have announced receipt of termination of listing advance notice, indicating a trend of companies leaving the capital market [1][3] - As of May 12, 2025, a total of 10 companies have received termination of listing advance notices from the Shanghai and Shenzhen Stock Exchanges, with additional companies like *ST Puli and *ST Xulan also facing similar fates [1][3] - The new delisting regulations have been implemented, leading to the first annual report season under these rules, resulting in multiple companies being warned of delisting risks and several directly delisted [5] Group 2 - *ST Renle reported a net asset of -387 million yuan for 2023 and -404 million yuan for 2024, triggering termination of listing due to financial report issues [3] - *ST Hengli's 2023 net profit was negative, and its revenue was below 100 million yuan, leading to a delisting risk warning [3][4] - *ST Zhongcheng's 2023 net asset was also negative, and its 2024 financial report received a qualified opinion, resulting in a proposed termination of listing [3][4] Group 3 - A total of 9 companies have completed delisting in 2025, with reasons ranging from continuous low stock prices to major violations [6][7] - The companies that have delisted include *ST Meixun, Haitong Securities, and *ST Boxin, among others, with various reasons for their delisting [7][8] - The trend indicates a significant number of companies facing financial difficulties and regulatory challenges, leading to increased scrutiny and potential delisting [10] Group 4 - The Beijing Stock Exchange may see its first delisted company, with Guandao Digital and Yun Chuang Data facing delisting risks due to audit issues [9][10] - Both companies have received audit opinions that could lead to termination of listing if they continue to meet financial delisting criteria in 2025 [10] - A total of 96 companies in the A-share market have been warned of delisting risks due to various financial issues, indicating a broader trend of financial instability among listed companies [10]

Core Viewpoint - The company, Hainan Puli Pharmaceutical Co., Ltd., has announced a potential downward adjustment of the conversion price for its convertible bonds due to the stock price falling below a specified threshold over a recent trading period [1][10]. Group 1: Convertible Bond Details - The company issued 8.5 million convertible bonds with a face value of 100 RMB each, raising a total of 850 million RMB, netting approximately 837.86 million RMB after fees [2][4]. - The conversion period for the bonds started on August 23, 2021, and will last until the bonds mature [4]. - The initial conversion price was set at 46.22 RMB per share, which has been adjusted multiple times due to various corporate actions [6][7]. Group 2: Price Adjustment Conditions - According to the bond's offering document, if the stock price falls below 85% of the conversion price for at least 15 out of 30 consecutive trading days, the board can propose a downward adjustment of the conversion price [10][11]. - As of the period from March 17, 2025, to May 9, 2025, the stock has recorded 10 trading days where the closing price was below 2.55 RMB, indicating a potential trigger for the price adjustment [1][10]. Group 3: Future Implications - If the downward adjustment condition is triggered, the company will follow the necessary procedures for board review and shareholder voting as outlined in the offering document [11][12]. - The company has a timeline for the delisting of its stock, with a trading suspension expected to last for 15 days, concluding on May 21, 2025 [1].

Core Viewpoint - Hainan Puli Pharmaceutical Co., Ltd. announced that its stock and convertible bonds will be delisted, with the delisting period starting on April 28, 2025, and expected to last until May 21, 2025 [1][2][3] Group 1: Delisting Information - The convertible bonds will enter a delisting adjustment period for fifteen trading days, with the last trading date anticipated to be May 21, 2025 [1] - After the delisting, the company's stock and convertible bonds will be managed by the National Equities Exchange and Quotations (NEEQ) in a delisting board for transfer [3] - The Shenzhen Stock Exchange has decided to terminate the listing of the company's stock and convertible bonds as of April 18, 2025 [2] Group 2: Management and Compliance - The company is required to appoint a securities firm to provide services for the transfer of its stock and convertible bonds in the delisting board [3][4] - The company has signed an agreement with Guotai Junan Securities Co., Ltd. to act as the main underwriter for the transfer of its stock and convertible bonds [4] - The appointed underwriter will handle various administrative tasks, including registration and confirmation of shares and bonds in the delisting board [4][5]